IntelliCyt, a provider of integrated platforms to accelerate drug discovery, antibody discovery and immunology, announced it has completed $7.4 million in new financing that consists of $5.4 million in venture financing and an additional $2 million debt facility.

IntelliCyt said the venture financing was led by Arboretum Ventures with participation from other current investors Prolog Ventures, Verge Fund, and New Mexico Community Capital.

The debt financing was led by Oxford Finance, a specialty finance firm that provides senior debt to life sciences and healthcare service companies.

“We are grateful for the continued support of our current investors and Oxford,” said R. Terry Dunlay, president and CEO of IntelliCyt. “We are rapidly growing and these funds will be used to continue to scale our commercial efforts globally and expand our product offerings to rapidly accelerating markets including immuno-oncology.”

“IntelliCyt’s integrated platform solutions are playing an increasingly important role in high-growth markets throughout the life sciences,” stated Tim Petersen, managing firector at Arboretum. “IntelliCyt is experiencing rapid sales growth, and with this new funding the company is positioned to accelerate its growth and enhance its position as a leading provider of a transformative, next-generation platform for cell and bead-based analyses to optimize breakthrough therapies for precision medicine.”

“Oxford is pleased to provide additional growth capital to support the broad adoption of IntelliCyt’s products” said Christopher A. Herr, senior managing director for Oxford Finance. “The company’s revolutionary instrument, reagent and software solutions are being embraced by biotech, pharmaceutical, and leading research institutes throughout the world.”

Albuquerque, NM-based IntelliCyt develops innovative tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes.